Performance of REMS Bone Densitometry in a British Population

Condition(s) studied

Investigational drug(s) / intervention(s)

REMS: Bone health assessment using REMS, an ultrasound technology developed to measure bone mineral density and bone toughness without ionising radiation

Study summary

Radiofrequency echographic multispectrometry (REMS) is a recently developed technology that uses ultrasound to assess bone density and bone quality. It was launched in 2018 since when OsteoscanUK Ltd has offered a clinical bone health service using a REMS scanner. REMS is an alternative to x-ray based dual energy x-ray absorptiometry (DEXA) scans which are considered the "Gold Standard" for clinical densitometry. REMS is unique in offering not only bone density but also bone quality assessments in real time for both the spine and hip.

Eligibility

Primary outcome measure(s)

• Longitudinal assessment of the change in bone mineral density (BMD) and bone toughness (Fragility Score) and correlation with fragility fracture status, age, menopausal status and body mass index, — 5 years for collection of sufficient data for meaningful analysis
  Analysis of the change in bone health parameters measured by REMS from the start of the study until final follow-up which will be at least 24 months

Trial sites (1)